Mumbai, March 21 -- US drugmaker Eli Lilly & Co. brought its anti-obesity drug Mounjaro to India on Thursday, marking the country's first treatment of its kind, with monthly costs ranging from Rs.14,000 to Rs.17,500. The new drug, however, will face competition soon enough, with other foreign pharmaceutical companies planning to introduce similar products in a growing market.

Mounjaro's 2.5mg and 5mg vials will be priced at Rs.3,500 and Rs.4,375 respectively, in India. The injectable drug, used to treat obesity and type-2 diabetes, is to be taken once a week. The company had previously stated that it would price the drug, which costs around $1,000 per month ( Rs.86,315) in the US, competitively in India. "This India-specific pricing refl...